Form 4: Ultragenyx CEO Emil Kakkis Reports Stock Transactions
SEC Form 4 Filing
Ultragenyx Pharmaceutical Inc.'s CEO, Emil Kakkis, reports acquisition and disposal of company stock and stock options.
Summary
- On March 1, 2024, Emil Kakkis, the President & CEO of Ultragenyx Pharmaceutical Inc., reported transactions involving the company's stock.
- Kakkis acquired 38,428 shares of common stock through the award of Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan.
- These RSUs vest in equal installments over four years from the grant date.
- He also disposed of 17,417 shares to cover tax withholdings related to the vesting of RSUs at a price of $53.69 per share.
- Additionally, 3,132 shares were acquired upon conversion of previously granted performance stock units after the performance metric was certified.
- Kakkis was also granted an option to buy 70,094 shares of common stock at an exercise price of $53.69, vesting over four years from the grant date.
- Following these transactions, Kakkis directly owns 563,913 shares and indirectly owns 2,263,985 shares through a living trust.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The transactions are routine and reflect standard executive compensation practices. The granting of RSUs and stock options suggests confidence in the company's future performance.
Positives
- The grant of RSUs and stock options to the CEO aligns his interests with the long-term performance of the company.
- The vesting schedule of the RSUs and stock options encourages continued service and dedication from the CEO.
Negatives
- The disposal of shares to cover tax obligations, while common, slightly reduces the CEO's direct stake in the company.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors regarding the buying and selling activities of company executives and directors.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
- The vesting schedules of the RSUs and stock options align executive interests with long-term shareholder value.
Key Dates
| Date | Description |
|---|---|
| June 18, 2009 | Date of Emil Kakkis and Jenny Soriano Living Trust |
| March 1, 2024 | Date of stock and derivative transactions, including RSU award, tax withholding disposal, performance stock unit conversion, and stock option grant |
| March 5, 2024 | Date of signature for the Form 4 filing |
| March 1, 2034 | Expiration date of the stock option granted on March 1, 2024 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.